Oculis boðar til rannsóknar- og þróunardags (e. R&D Day) bæði í streymi og á staðnum: Framþróun þróunarlyfja með skýra sérstöðu á síðari stigum klínískrar þróunar

Oculis Holding AG announced an R&D Day scheduled for December 8, 2026, to present clinical and strategic milestones for its late-stage development drugs. Licaminlimab, eye drops containing a TNF-α inhibitor for dry eye disease, has completed patient randomization in the PREDICT-1 registrational trial with topline results expected around year-end. Privosegtor, a neuroprotective therapy for optic neuritis and other neuro-axonal diseases, is advancing through the PIONEER program with an anticipated IND application approval this quarter. The company will feature leading international ophthalmology and neurology experts at the virtual and in-person event.